Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment.

ABSTRACT:

Background

Ticagrelor is a first-line drug for the treatment of acute ST elevation myocardial infarction (STEMI). However, approximately 20% STEMI patients taking ticagrelor exhibited a delayed response and the mechanism was still unclear.

Methods

To explore the mechanism of the poor response of ticagrelor in post-percutaneous coronary intervention (PCI) patients, we enrolled 65 high platelet reactivity (HPR) patients and 90 controls (normal platelet reactivity [NPR]). Pharmacokinetic assessment result showed that the plasma concentrations of ticagrelor and its metabolism production, AR-C124910XX, were lower in HPR patients than controls. Further single nucloetide polymorphism (SNP) analysis identified that there is no difference in ATP binding cassette subfamily B member 1

SUBMITTER: Zhang X 

PROVIDER: S-EPMC8903831 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature